Global Single-Use Bioreactors Market Assessment, By Product [Single-use Bioreactor Systems, Single-use Media Bags, Single-use Filtration Assemblies and Accessories], By Type of Module [Stirred-Tank SUBs, Wave-Induced SUBs, Bubble-Column SUBs, Other], By Cell Type [Mammalian Cells, Bacterial Cells, Yeast Cells, Other], By Application [Bioproduction, Process Development, Research and Development], By End-user [Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Academic and Research Institutes], By Region, Opportunities and Forecast, 2018-2032F

Global single-use bioreactors market is projected to witness a CAGR of 18.37% during the forecast period 2025-2032, growing from USD 4,225.72 million in 2024 to USD 16,025.94 million in 2032. The single-use bioreactors market is an important part of the healthcare industry, accounting for a significant market size in the healthcare market. Factors such as reduced risk of contamination, technological advancements, increased adoption among startups and SMEs (small and medium-sized enterprises), and advantages over traditional bioreactors drive the market growth. The disposable bioreactor market is fast-changing as biopharmaceutical companies more and more implement disposable bioreactor systems to improve flexibility, speed, and efficiency in drug development and manufacture. These pre-sterilized, disposable bag and component-based systems pose several advantages over conventional stainless-steel bioreactors, such as lower risk of cross-contamination, removal of cleaning and validation processes, and lower installation and maintenance costs, making them highly suitable for small biotech companies, contract manufacturing organizations, and biotherapeutic and biosimilar manufacturers of personalized medicines. The growth in biologics, vaccines, and cell and gene therapies is driving demand for scalable and modular bioprocessing technologies, with single-use bioreactors facilitating quicker product development cycles and simpler compliance with rigorous regulatory demands. Advances in technology have enhanced the reliability, safety, and material quality of these systems, while continued innovation is meeting extractables, leachable, and batch-to-batch performance consistency concerns. In spite of these advantages, the market is hampered by such challenges as the greater initial cost of production compared to stainless steel systems, the necessity for more standardization among suppliers, and complexities in sterility assurance during assembly and operation.

The market for single-use bioreactors in the bioprocessing sector is dedicated to the design, production, and deployment of single-use bioreactor systems for a range of biopharmaceutical and biotechnology uses. These systems reduce the demand for conventional stainless-steel bioreactors by offering effective and affordable solutions for cell culture activities including fermentation, protein expression, and cell growth. Biopharmaceutical firms used versatile technology that brought online response to the pandemic, increasing the requirement for quick mass manufacturing of vaccines against the SARS-CoV-2 virus. Single-use systems witnessed huge demand due to coronavirus and the need for large-scale vaccine manufacturing at a fast pace. This led to the expansion of the single-use bioreactors market post pandemic.

In March 2025, “Project Nexus,” a collaboration between the UK government’s UK Innovate scheme and the Centre for Process Innovation Limited with a budget of USD 2.45 million, included Photocentric Ltd, Sartorius AG and Sheffield University. The project's goal is the creation of sustainable bio-based materials for single use bioprocessing technologies such as bioreactors. It incorporates advanced 3D printing and utilizes biocompatible resins to reduce plastic waste, enhance recyclability, and support circular economic concepts. The project aims to transform bioprocessing through novel materials and sustainable approaches alongside net-zero ambitions. It shifts the paradigm of how bioprocessing is approached within the context of increasing concerns surrounding climate change and the environment, balancing the growth of the biopharmaceutical market with environmental consciousness.

Single-use Bioreactors Offer Clinical Advantages Over Traditional Bioreactors

When compared to stainless steel bioreactors (SSBs), single-use bioreactors (SUBs) have been demonstrated to significantly reduce water consumption and facility energy use. Disposing of single-use parts, however, presents issues with waste production and possible environmental effects. Single-use bioreactors require less maintenance, have quick setup periods, and are simpler to customize in terms of reactor size and configuration as they provide greater flexibility. In research and development applications, where process development is continuous, and production quantities are low, single-use bioreactors can be useful. Additionally, SUBs have shown themselves to be significantly more helpful in facilities that produce many products and in situations where process flexibility is crucial in terms of quantities and product needs. For example, in March 2025, ABEC launched the Advanced Therapy Bioreactor (ATB), a revolutionary single-use bioreactor for Advanced Therapy Medicinal Products (ATMPs). Imitating the human circulatory system, it employs hollow fiber membranes for localized delivery of nutrients and waste removal to support maximum growth. The ATB provides smooth scalability (0.2L to 10L) and closed-system automated operation. It showed high cell viabilities and cell densities for T-cells, CD34+ stem cells, HEK293, and CHO cells. This technology overcomes limitations in advanced therapy manufacturing, which speeds up clinical and commercial timelines while ensuring uniform cell culture conditions on all scales.

Avoiding Risk of Cross-Contamination and Improving Compliance Facilitate the Market Growth

The market for single-use bioreactors continues to grow because bioreactors can be used to reduce cross-contamination events when applied in multi-product biologic manufacturing systems. Stainless steel equipment requires thorough cleaning and sterilization procedures that involve significant labor in terms of worker time and subject the process to human errors, which may introduce contaminating substances to the system. One of the examples pointing out this benefit is the application of BioBLU Single-Use Bioreactors by Eppendorf with sealed magnetic drives to avoid microbial contamination and becoming pre-sterilized and thus eliminating cleaning validation entirely. This technology is extensively used across the biopharmaceutical market, enabling the companies to achieve streamlined operations along with high quality products and regulations. Consequently, the increasing demand for single-use systems is transforming manufacturing processes. For instance, In July 2024, Avantor, Inc. launched two new high-performance reagents for gene therapy manufacturing, J.T. Baker Cell Lysis Solution and J.T. Baker Endonuclease. These reagents will improve the process efficiency and reduce the contamination risk.

Technological Advancements to Advance the Global Single-use Bioreactors Market

Recent substantial technological improvements have led to an increased utilization of single-use bioreactors in biopharmaceutical production. Manufacturers are coming up with new ideas to enhance single-use bioreactor film technologies, designs, stirring motors, and sensor systems. Single-use bioreactors are more effective and efficient for developing cell cultures on a large scale due to such advancements. Improved sensor systems for better process monitoring, control, and improvements in the materials and designs of bioreactor bags can promote cell growth and productivity, including other significant advancements. The AMBR 250 modular, a novel benchtop small bioreactor system for parallel fermentation or cell culture, was launched by Sartorius Stedim Biotech. This system gives bioprocess scientists access to advanced benchtop bioreactor technology for process research by combining a special single-use bioreactor vessel with a flexible system architecture. For instance, in September 2023, Getinge launched the AppliFlex ST GMP, a next-generation single-i bioreactor system that allows bioprocesses to easily move from research in the laboratory to clinical manufacturing. The system is specifically suited for cell and gene therapy processes and mRNA manufacturing, providing scalability and Good Manufacturing Practice (GMP) compliance. In another instance, on March 31, 2025, ABEC, Inc. introduced the Advanced Therapy Bioreactor (ATB), a groundbreaking single-use bioreactor for Advanced Therapy Medicinal Products (ATMPs). Mimicking the human circulatory system, it uses hollow fiber membranes for localized nutrient delivery and waste removal, ensuring optimal cell growth. The ATB offers seamless scalability (0.2L to 10L) and automated, closed-system operation. It demonstrated high cell densities and viabilities for T-cells, CD34+ stem cells, HEK293, and CHO cells. This innovation addresses challenges in advanced therapy manufacturing, accelerating clinical and commercial timelines while maintaining consistent cell culture conditions across all scales.

Single-use Bioreactor Systems to Dominate Market

In 2024, the single-use bioreactor systems segment accounts for the highest market share in the global single-use bioreactors market. Systems for single-use bioreactors are frequently used in biopharmaceutical manufacturing procedures when a high product yield is necessary. Single-use bioreactors' adaptability, affordability, and high capacity for mass production would spur consumer demand and propel the industry's rapid expansion. The need for faster discovery and increased production of novel bio-therapeutics, such as vaccines, antibodies, enzymes, and hormones, and a rise in the product quantities that these bioreactors can generate are expected to drive the growth of market. Over the forecast period, the category will rise due to major manufacturers' increased focus on providing small-scale bioreactors.

In June 2024, WuXi Biologics Cayman Inc, a CRDMO, announced that its pharmaceutical manufacturing plant in Hangzhou had installed three sets of 5,000L single-use bioreactors in the second drug substance line. The facility's overall capacity will rise from 8,000L to 23,000L due to the recently installed bioreactors, substantially enhancing the company's manufacturing capabilities for clients throughout the world.

North America Leads the Single Use Bioreactor Market

North America is the biggest player in the single-use bioreactor market worldwide, thanks to the widespread presence of prominent biopharmaceutical firms, strong uptake of next-generation bioprocessing technology, and a highly developed regulatory regime. The United States dominates the region with large investments in biologics, biosimilars, and manufacturing of cell and gene therapies. The increasing activity of CDMOs and biopharma growth in Canada and Mexico is further driving market expansion. Further, positive government policies, growth in R&D spending, and the swift movement towards flexible and scalable single-use manufacturing solidify North America’s global market dominance. For instance, in November 2024, Avantor, Inc. inaugurated its new Bridgewater Innovation Center in New Jersey, United States. This state-of-the-art facility tackles critical challenges in life science, biopharma, and advanced technological sectors. The center focuses on scientific collaboration, material innovation, and process optimization to accelerate drug development and manufacturing.

Asia-Pacific is Expected to Grow at the Fastest Pace in the Forecast Period

The single-use bioreactor market in Asia-Pacific is anticipated to grow at a high CAGR due to generic medicine manufacturers and recent biosimilar industry players based in the region. It faces commercial pressure to quickly scale up production utilizing disposable technology at reduced prices. Growing population and changing disease patterns are driving the demand for biopharmaceuticals and vaccines throughout Asia. Local companies have opted for single-use solutions to expedite facility construction and accelerate their services in the market.

In the second half of 2024, Syngene International Ltd, a global contract research, development, and manufacturing organization (CRDMO), will begin clinical and commercial supply of its recently renovated biologics facility (Unit 3) in Bangalore, India, to clients in the United States and Europe. With two production chambers and five 2KL single-use bioreactors each, the machines have a production capacity of 20KL.

Download Free Sample Report

Future Market Scenario (2025-2032F)

• The biopharmaceutical manufacturing sector is rapidly adopting single-use bioreactors as they are better than traditional systems in numerous ways. Advantages include faster turnaround times between production runs, reduced risk of cross-contamination, and lower capital investment.
• Single-use bioreactors are predominantly employed in the manufacturing of biopharmaceuticals. However, their usage extends to other areas such as the food and beverage industry, agriculture, and environmental science sector.
• More sustainable practices are being supported by single-use bioreactors such as sustainability, which is increasingly becoming an urgent challenge in biomanufacturing. These practices will reduce waste generation, save energy expenses through reducing water and chemical usage and eliminating cleaning and sterilization requirements.
• Continuous technological advancements are expected to enhance the performance and reliability of single-use bioreactors in the future. New technologies that can become part of single-use bioreactors include advanced sensors for real-time monitoring, integration of artificial intelligence (AI), machine learning (ML), 3D printing, and IoT devices.

Report Scope

“Single-use Bioreactors Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global single-use bioreactors market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2024
Historical Period	2018-2023
Forecast Period	2025-2032
Projected Growth Rate	CAGR of 18.37% between 2025 and 2032
Revenue Forecast in 2032	USD 16,025.94 million
Segments Covered	Product, Type of Module, Cell Type, Application, End-user
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profile	Sartorious AG, Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Getinge AB, Eppendorf AG, Entegris Inc, Avantor Inc, Celltainer Biotech BV, Cellexus Ltd
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global single-use bioreactors market has been segmented into the following categories: 

• By Product
  • Single-use Bioreactor Systems
    • Up to 100L
    • 101-1500L
    • Above 1500L
  • Single-use Media Bags
    • 2D Bags
    • 3D Bags
  • Single-use Filtration Assemblies and Accessories
  • Other Products
• By Type of Molecule
  • Stirred-Tank SUBs
  • Wave-Induced SUBs
  • Bubble-Column SUBs
  • Other
• By Cell Type
  • Mammalian Cells
  • Bacterial Cells
  • Yeast Cells
  • Other
• By Application
  • Bioproduction
  • Process Development
  • Research and Development
• By End-user
  • Pharmaceutical and Biotechnology Companies
  • Clinical Research Organizations
  • Academic and Research Institutes
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

Several medical device companies and biotech companies are flourishing in the single-use bioreactors market by planning and adopting new strategies. They are complying with new strategic initiatives for antimicrobial susceptibility testing devices to increase their market presence. New agreements, contracts, acquisitions mergers, investments, and partnerships are major ways through which they try to achieve higher market share.

In August 2023, Repligen XCell ATF upstream intensification technology was incorporated into Sartorius Stedim Biotech Inc’s Biostat STR bioreactor as part of an integrated bioreactor system. A completely compatible embedded XCell ATF hardware and software module that offers predefined advanced control recipes with integrated Process Analytical Technology (PAT) is now included in the Biostat STR. A single point of control for 50 L–2000 L upstream intensification processes, developed by the integration of the XCell Controller hardware and software into the Biobrain automation platform, allowing clients to make greater use of their facility space with a smaller equipment footprint.

In September 2024, Getinge AB completed the acquisition of Paragonix Technologies, Inc., a leading organ transport products and services company. This strategic move strengthens Getinge's position in the organ preservation and transportation market, leveraging Paragonix's innovative technologies and expanding global healthcare solutions.

In June 2024, Aragen Bioscience, Inc. successfully validated Getinge AB’s SUPR bioreactor (Single-Use Production Reactor) for large-scale recombinant antibody production. The study demonstrated the SUPR system’s exceptional performance in generating high-quality recombinant antibodies.

Key Players Operating in Global Single-use Bioreactors Market are:

• Sartorious AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Getinge AB
• Eppendorf AG
• Entegris Inc
• Avantor Inc
• Celltainer Biotech BV
• Cellexus Ltd

If you can't find what you're searching for or have any custom requirements for global single-use bioreactors market, you may approach our team at info@marketsandata.com